

#### Available online at www.jbr-pub.org.cn

#### Open Access at PubMed Central



The Journal of Biomedical Research, 2020 34(2): 86-93

Review Article

# Contribution of neutrophils in the pathogenesis of rheumatoid arthritis

Lingshu Zhang<sup>1,2</sup>, Yi Yuan<sup>3</sup>, Qiang Xu<sup>1,2</sup>, Zhengyu Jiang<sup>3</sup>, Cong-Qiu Chu<sup>1,2,∞</sup>

#### Abstract

Neutrophils are major innate immune effector cells for host defense and have been a topic of active research for their participation in the pathogenesis of autoimmune inflammatory diseases including rheumatoid arthritis (RA) due to recently discovered neutrophil extracellular trap (NET) formation. NET formation and other mechanisms leading to the release of neutrophil nuclear and cytoplasmic contents are implicated as a source of citrullinated antigens in RA. Further investigations are required to delineate what factors diverge neutrophils from host defense to autoimmune response in RA.

**Keywords:** neutrophils, rheumatoid arthritis, NET formation

#### Introduction

Neutrophils play a pivotal role in the innate immune system for host defense in fighting microbe invasion. They migrate to the infection site as the first responders during acute inflammation. It has been well established that neutrophils kill pathogens *via* phagocytosis and degranulation<sup>[1–2]</sup>. A novel third mechanism was discovered by Brinkmann *et al*<sup>[3]</sup> in 2004 that neutrophils utilize to kill microbes and this was named neutrophil extracellular traps (NETs). The NETs are mainly composed of histones and DNA fiber which entrap and facilitate the killing of pathogens<sup>[3]</sup>. Indeed, neutrophils undergone NET formation are identified *in situ* in surgically excised appendicitis tissue in humans<sup>[4]</sup> implying NET formation involves fighting microorganisms *in vivo*.

Received 19 May 2019, Revised 30 June 2019, Accepted 20 August 2019, Epub 24 October 2019

CLC number: R593.22, Document code: A

The authors reported no conflict of interests.

This is an open access article under the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.

<sup>&</sup>lt;sup>1</sup>Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR 97239, USA;

<sup>&</sup>lt;sup>2</sup>Rheumatology Section, VA Portland Healthcare System, Portland, OR 97239, USA;

<sup>&</sup>lt;sup>3</sup>Department of Rheumatology and Immunology, the First Hospital of Jilin University, Changchun, Jilin 130021, China.

Since the discovery of NETs, the field of research has been extremely active and continues to expand. Contribution of NET formation to the pathogenesis of autoimmune chronic inflammation has implicated because of extracellular extrusion of DNA and histones and other proteins that stimulate immune responses leading to the subsequent inflammatory process and cause tissue damage<sup>[5]</sup>. However, controversy and confusion have been generated due to contradictory results and divergent concepts<sup>[6–7]</sup>. NET formation has been interchangeable with NETosis, a term coined by Steinberg and Grinstein to distinguish its difference from apoptosis and necrosis[8]. The initial description of NET formation for bacteria killing-appears to be more physiological, i.e., neutrophils are activated by bacteria, lipopolysaccharide (LPS), interleukin (IL)-8

<sup>&</sup>lt;sup>™</sup>Corresponding author: Cong-Qiu Chu, Division of Arthritis and Rheumatic Diseases, Oregon Health &Science University and Rheumatology Section, VA Portland Healthcare System, Portland, OR 97239, USA. Email: chuc@ohsu.edu.

or a low concentration of phorbol 12-myristate 13-acetate (PMA). The release of DNA, histones, granule proteins by neutrophils are independent of cell death. In other words, viable neutrophils form NETs to control pathogens. The neutrophil cell death referred to as NETosis was obtained following non-physiological stimulation such as a high dose of PMA with a significantly longer duration<sup>[6–9]</sup>. Therefore, it has been suggested by a large group of scientists that NETosis should be abandoned or only be used where the demise of the neutrophil is obvious<sup>[6–7]</sup>, in particular, not to be used to describe NET formation in a physiological situation.

Studies of neutrophils in RA have been focused on their role in protein citrullination in RA. NET formation (or NETosis as has been commonly referred in literature) has been linked to the citrullination of proteins in RA<sup>[10]</sup>. However, this notion has been challenged by other investigators who argue that leukotoxic hypercitrullination (LTH) and defective mitophagy of neutrophils are likely the mechanisms for the generation of citrullinated autoantigens in RA<sup>[11]</sup>. In comparison to the debatable notion regarding how neutrophils contribute to citrullination, the cytotoxic effects and inflammatory cytokine production by neutrophils in the pathogenesis of RA are generally accepted<sup>[12–14]</sup>.

### Neutrophils as effector cells in RA inflammation and tissue destruction

Neutrophils are the most abundant cell type present in synovial fluid in patients with RA[15] although are fewer in the synovial tissue[16-17], but are in a larger number at the cartilage-pannus junction where synovial tissue invades cartilage[18]. Neutrophils in the site of inflammation have become activated and display longevity[19]. Neutrophils in RA patients are functionally different from those of healthy individuals since neutrophils in RA blood are already primed for reactive oxygen species production[20]. Among the cell types implicated in RA pathology, neutrophils have the greatest cytotoxic potential. Indeed, depletion of neutrophils significantly reduces the severity of experimental arthritis which implies the essential role of neutrophils in the pathogenesis of RA<sup>[21]</sup>. This has been confirmed by therapeutic effects in clinical practice where many efficacious agents affect neutrophils[14] although these were not originally aimed at targeting neutrophils. These agents include corticosteroids, methotrexate, tumor necrosis factor (TNF) inhibitors, IL-6 receptor blocker and JAK inhibitors<sup>[14]</sup>. The cytoplasmic granules of neutrophils contain various serine proteases which can be released upon stimulation. Immune complexes containing anticitrullinated protein antibodies (ACPA) rheumatoid factor (RF) in RA joint can trigger neutrophil degranulation through FcyR<sup>[22]</sup>. For example, neutrophil elastase and cathepsin G process IL-33, an IL-1 family cytokine, into three bioactive forms. Moreover, these forms of IL-33 can be produced by neutrophils in vivo<sup>[23]</sup>. Neutrophil elastase and collagenase cleave collagen, elastin and lubricin which directly involve cartilage damage[24-25]. Mice with deficiency in full activation of cathepsin G, neutrophil elastase and proteinase 3 are defective in the local production of IL-1ß and TNF and are resistant to induction of experimental arthritis[26]. These results provide direct evidence indicating the importance of these proteases in causing inflammation in arthritis.

Myeloperoxidase (MPO) is the most abundant cytotoxic enzyme in the azurophilic granules of neutrophils. Increased levels of MPO are present in RA plasma, synovial fluid and tissue<sup>[27–28]</sup>. In addition to its microbicidal functions, MPO interacts with vascular endothelial cells to increase endothelial permeability which is a critical process during inflammation<sup>[29]</sup>. Moreover, MPO also potently attracts more neutrophils to the site of inflammation<sup>[30]</sup> to amply the reaction. MPO triggers inflammatory cytokine production to further exacerbate the inflammation. In vitro, MPO can enhance proliferation but decrease apoptosis of RA synovial fibroblast-like synoviocytes<sup>[28]</sup>. Mice deficient in endogenous MPO significantly attenuated K/BxN arthritis and collageninduced arthritis<sup>[28]</sup>.

### Neutrophils regulate immune and inflammatory response in RA

Neutrophils in RA joint become activated likely by the microenvironment and the activated neutrophils are resistant to apoptosis and can survive for several days compared to the short life span of 24 hours in peripheral blood<sup>[31–32]</sup>. Besides secreting proteases, activated neutrophils act like macrophages or dendritic cells in the regulation of adaptive immune response. RA synovial fluid neutrophils secrete a number of inflammatory TNF family cytokines including TNF[33-34], B cell-activating factor (BAFF)[35] and receptor activator of nuclear factor kappa B ligand (RANKL)[36]. BAFF is a B cell growth factor that induces B cell proliferation and contributes autoantibody production in RA[37]. RANKL mediates osteoclast differentiation and is the major factor causing bone erosion in RA[38]. Activated neutrophils also express chemokines and chemokine receptors which facilitate the migration of and infiltration of neutrophils in RA joint[39-41]. Genetic deficiency or pharmacological inhibition of CCR2 abolishes neutrophil infiltration into the joints<sup>[39]</sup>. It has been shown that neutrophils can acquire the capacity of antigen presentation *in vitro* and *ex vivo* to autologous memory CD4+ T cells in a major histocompatibility complex II (MHC II) dependent manner<sup>[42]</sup>. This property of neutrophils has been observed in RA. Thus, RA joint neutrophils express MHC-II. These MHC-II expressing neutrophils can present antigen and stimulate CD4+ T cells proliferation<sup>[43]</sup>. These results indicate that activated neutrophils gained function to regulate T and B cell function.

#### **NET formation in RA**

Enhanced NET formation in neutrophils of RA patients has been observed by many studies[44-53]. Interestingly, one study suggests that the plasma level of cell-free nucleosome can be used as a biomarker for the identification of RA patients with high specificity and sensitivity<sup>[48]</sup>. Neutrophils in the peripheral blood and synovial fluid of RA patients display a propensity of spontaneous formation of NETs. Furthermore, NET formation of RA neutrophils is further enhanced by stimulation when compared with those neutrophils isolated from the blood of healthy individuals or synovial fluid of patients with osteoarthritis (OA). This implies that neutrophils in RA patients have been primed to form NETs in vivo which is evident by the presence of NET forming neutrophils in RA synovial tissue, rheumatoid nodules, and neutrophilic dermatoses. RA joint contain stimuli that are capable of inducing NET formation. These include IgA RF containing immune complex<sup>[46]</sup>, purified IgG from RA plasma<sup>[54]</sup>, ACPA and RF in the synovial fluid and inflammatory cytokines such as TNF and IL-17A<sup>[44]</sup>. In particular, ACPA against citrullinated vimentin which suggested to be pathogenic in RA potently induce NET formation of neutrophils from both healthy controls and RA patients. These results suggest that inducing NET formation in RA is one of the mechanisms that ACPA mediate the disease. Interestingly, TNF and IL-17A synergize in inducing NET formation of RA neutrophils, i.e., TNF priming significantly increased the NET forming induced by IL-17A<sup>[44]</sup>.

Mechanisms of NET contribution to the pathogenesis of RA have been investigated. First, NETs can promote inflammatory property of fibroblast-like synoviocytes (FLS). When FLS are exposed to NETs, NETs can be internalized by FLS. FLS from both RA and OA can be stimulated by NETs and secrete significantly increased levels of IL-6<sup>[44]</sup>. The internalization is Toll-like receptor (TLR)-9

mediated. Furthermore, NET internalization induces MHC-II upregulation by FLS. Arthritogenic NET peptides are loaded onto the MHC II compartment and can be presented to and activate CD4+ T cells<sup>[55]</sup>. Most strikingly, humanized HLA-DRB\*04:01 produce transgenic mice **ACPA** can immunization with NETs loaded FLS. These ACPA recognize α-enolase, citrullinated fibrinogen and citrullinated vimentin which all are highly specific for RA. These ACPA production is CD4+ T cell dependent. These animals also display pannus formation and cartilage degradation, although an overt clinical arthritis was not observed<sup>[55]</sup>. NET contains mainly citrullinated histones. Citrullinated H2B histones are present in high levels in RA synovial fluid in >90% of RA patients studied. These citrullinated H2B histones were able to stimulate macrophages to produce TNF and propagate neutrophil activation. Furthermore, immunization of mice with citrullinated H2B histone demonstrated that they were also arthritogenic in the setting that mice have been primed by anti-collagen type antibodies[56]. These results may imply citrullinated proteins contained in NETs may have triggered the immune response in vivo in immunized mice. ACPA production is a hallmark of RA. However, how ACAP is initiated has remained elusive. NET formation has been considered to be the source of citrullinated autoantigens and may have initiated the autoimmunity to citrullinated proteins in RA[10,57]. Khandpur et al demonstrated that induced NETs from both healthy individuals and RA patients contain citrullinated vimentin<sup>[44]</sup>. More relevant to the disease is that spontaneously formed NETs from RA patients contain citrullinated vimentin which binds to ACPA<sup>[44]</sup>. Citrullination of histones is a critical step in the initiation of NET formation and citrullinated histones comprise around 70% of all NET proteins[10]. Autoantibodies against citrullinated histones are readily detected in RA sera and synovial fluid[50-51,56,58]. About 40% of recombinant monoclonal antibodies derived from ACPA positive RA patient synovial tissue display reactivity against citrullinated histones<sup>[59]</sup>. Interestingly, anti-citrullinated histones can be detected many years before RA develops in atrisk population[51,58,60]. NETs may release citrullinated histones that trigger immune response to produce antibodies against these modified proteins and subsequently ACPA recognize other citrullinated proteins are produced along with established inflammation.

### Leukotoxic hypercitrullination of neutrophils and RA

Despite that these studies suggest NETs provide

citrullinated proteins as antigens for ACPA production in RA, this notion has been challenged[11,61]. Andrade and colleagues suggest that a different form of cell death of neutrophils which is similar but distinctively different from NET formation is the source of citrullinated proteins in RA joint[11,61-64]. It has been demonstrated that citrullination in the RA joint is cellassociated and that a broad range of proteins are citrullinated. This pattern of citrullination was termed "cellular hypercitrullination" which is prominently immune-mediated induced by membranolytic pathways causing cell membrane pore formation, such as the action by perforin and membrane attack complex (MAC) of activated complements. Owing to nature and cytotoxicity in hypercitrullination, the membranolytic process was also termed "LTH". On the contrary, NET formation does not induce hypercitrullination observed in RA joint<sup>[64]</sup>. The so-called NET formation or NETosis in the literature was inappropriately claimed to contribute RA hypercitrullination<sup>[11,61]</sup>. Experimentally perforin and MAC caused neutrophil death trigger hypercitrullination and this process is calcium dependent. In other words, a surge of calcium influx precedes neutrophil death. Hypercitrullination is likely mediated by activation of peptidylarginine deiminase (PAD)-2, PAD3, and PAD4. These are all different from NET formation in which histone citrullination is catalyzed preferentially by PAD4[65]. Recently, Konig  $et \ al^{[62]}$ demonstrated Aggregatibacter actinomycetemcomitans, a pathogen causing periodontitis can cause cell death and hypercitrullination in neutrophils by secreting a poreforming toxin called leukotoxin A (LtxA). The spectrum of protein citrullination (citrullinome) of neutrophils induced by purified LtxA are markedly overlapped with citrullinome of RA synovial fluid[62]. This observation is relevant to the pathogenesis of RA. In a cohort of RA patients, up to 43% have shown previous A. actinomycetemcomitans infection vs. 11% in controls. Furthermore, the positivity of anti-LtxA antibodies (indication of A. actinomycetemcomitans infection) is significantly associated with the presence of ACPA and this association is more pronounced in RA patients bearing HLA-DRB1 alleles<sup>[62]</sup>.

## Mucosal sites as origin of RA-contribution of neutrophils

It has been hypothesized that RA may be initiated extraarticularly. This hypothesis is supported by that at-risk individuals do not display synovitis even as late as one week prior to clinical onset of arthritis<sup>[66]</sup>, but ACPA and RF can exist in the circulation for over

a decade before the clinical onset of arthritis<sup>[67–68]</sup>. This suggests that the autoimmune response has been in operation elsewhere precedes synovitis in the joint. Mucosal sites, in particular the lung, have been considered the sites for initiation of RA<sup>[69-70]</sup>. Inflammation in the lung is evident in some at-risk individuals at pre-clinical phase of RA<sup>[71]</sup>. In at-risk population who later develop RA, ACPA can be detected in the sputum before they appear in the serum<sup>[72-73]</sup>. These autoantibodies are likely produced locally at inducible bronchus-associated lymphoid tissue<sup>[74]</sup>. The question arises here is how ACPA in the lung are developed in the first place. NET forming neutrophils may contribute. Both IgA and IgG ACPA are detectable in the at-risk first-degree relatives of RA patients and the levels of these ACPA are associated with NET levels in the sputum<sup>[73]</sup>. NET formation in the lung has been associated with smoking and inflammation and both have been associated with RA<sup>[75-76]</sup>. As the first responders, neutrophils respond primarily to pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs). It can be hypothesized that in response to the insult by PAMPs or DAMPs, neutrophils are recruited into the lung where enhanced NET formation or LTH also takes place to generate citrullination of proteins to trigger ACPA production.

The other mucosal site inflammation associated with RA is the periodontium. Clinical epidemiology studies have linked periodontitis with RA[77-80] and there are cases that periodontitis precedes joint synovitis in RA[81]. Periodontitis may breach the immune tolerance by generating citrullinated proteins for production of ACPA[82]. The major periodontal pathogens Porphyromonas gingivalis and actinomycetemcomitans are implicated for aberrant citrullination in periodontitis and RA. P. gingivalis is the only known human pathogen that produces PAD (designated as PPAD to distinguish it from human PAD) which exhibits a specificity for C-terminal residue and generates citrullinated neoantigens of those implicated in RA<sup>[83–85]</sup>. While A. actinomycetemcomitans contribute to the citrullination of proteins by means of LTH in which A. actinomycetemcomitans may cause pore formation of the cell membrane of neutrophils and lead to hypercitrullination<sup>[62]</sup>. Evidence presented above is compelling to indicate that the citrullination of proteins generated outside of joint may initiate the breach of tolerance and ACPA production. However, it is not clear how the autoimmunity in the mucosal site is transferred into the joint (*Fig. 1*).




Fig. 1 Neutrophil centered etiology and pathogenesis of RA.

### Concluding remarks

The cytotoxic and proinflammatory properties of neutrophils are likely mediators for RA inflammation and tissue destruction. There is also compelling evidence to support the contribution by neutrophils to citrullination in RA. However, it is debatable how neutrophils initiate citrullination in RA. Many earlier studies observed extrusion of chromatin and citrullinated proteins by neutrophils from RA patients attributed to the results of NET formation.

The initial description of NET formation which is a host defense mechanism by neutrophils that is well regulated and is not necessarily involved in neutrophil death. It is apparent the so-called NET formation or NETosis observed in RA patients may all represent an aberrant NET forming which may have been intended for host defense but was dysregulated. This may offer explanation for infection as an etiology for RA. The recently described phenomenon of neutrophils, LTH offers an alternative explanation for citrullination in RA. LTH is primarily utilized by microbes to kill neutrophils and this process results in release of a broad range of protein citrullination. The citrullination status can be amplified or maintained by MAC. The major distinction between NET formation and LTH is that NET formation is a NADPH oxidase (NOX2)dependent process for neutrophils to kill microbes, whereas LTH is NOX2-independent process that is utilized by microbes to achieve immune evasion[11]. Both processes are able to generate citrullinated proteins, but NOX2-independent process generates hypercitrullination which may be more pathogenic. In an attempt to further delineate the citrullination spectra, Chapman et al<sup>[86]</sup> quantitatively analyzed the proteome generated by either NOX2-dependent or NOX2-independent mode. A broadly similar profile of protein citrullination can be induced by either mode. It is not clear whether the subtle difference between the

protein citrullination profiles are meaningful *in vivo* in terms of contribution to the disease pathogenesis in  $R \Delta$ 

#### Acknowledgments

CQC was supported by Rheumatology Research Foundation Innovative and Pilot grants and VA Merit Review grant (BX002858).

#### References

- [1] Borregaard N. Neutrophils, from marrow to microbes[J]. *Immunity*, 2010, 33(5): 657–670.
- [2] Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and regulation of innate and adaptive immunity[J]. *Nat Rev Immunol*, 2011, 11(8): 519–531.
- [3] Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria[J]. *Science*, 2004, 303(5663): 1532–1535.
- [4] Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin[J]. *J Cell Biol*, 2012, 198(5): 773–783.
- [5] Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellular traps in rheumatic diseases[J]. *Nat Rev Rheumatol*, 2018, 14(8): 467–475.
- [6] Yousefi S, Stojkov D, Germic N, et al. Untangling "NETosis" from NETs[J]. Eur J Immunol, 2019, 49(2): 221–227.
- [7] Boeltz S, Amini P, Anders HJ, et al. To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps[J]. *Cell Death Differ*, 2019, 26(3): 395–408.
- [8] Steinberg BE, Grinstein S. Unconventional roles of the NADPH oxidase: signaling, ion homeostasis, and cell death[J]. Sci STKE, 2007, 2007(379): pe11.
- [9] Takei H, Araki A, Watanabe H, et al. Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13acetate (PMA) accompanied by changes different from typical apoptosis or necrosis[J]. *J Leukoc Biol*, 1996, 59(2): 229–240.

- [10] Corsiero E, Pratesi F, Prediletto E, et al. NETosis as source of autoantigens in rheumatoid arthritis[J]. Front Immunol, 2016, 7: 485.
- [11] Konig MF, Andrade F. A critical reappraisal of neutrophil extracellular traps and NETosis mimics based on differential requirements for protein Citrullination[J]. Front Immunol, 2016, 7: 461.
- [12] O'Neil LJ, Kaplan MJ. Neutrophils in rheumatoid arthritis: breaking immune tolerance and fueling disease[J]. *Trends Mol Med*, 2019, 25(3): 215–227.
- [13] Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis[J]. *Nat Rev Rheumatol*, 2014, 10(10): 593–601.
- [14] Cecchi I, de la Rosa IA, Menegatti E, et al. Neutrophils: novel key players in rheumatoid arthritis. Current and future therapeutic targets[J]. *Autoimmun Rev*, 2018, 17(11): 1138–1149.
- [15] Cascão R, Rosário HS, Souto-Carneiro MM, et al. Neutrophils in rheumatoid arthritis: more than simple final effectors[J]. Autoimmun Rev, 2010, 9(8): 531–535.
- [16] Tak PP, Smeets TJM, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity[J]. *Arthritis Rheum*, 1997, 40(2): 217–225.
- [17] Palmer DG, Hogg N, Revell PA. Lymphocytes, polymorphonuclear leukocytes, macrophages and platelets in synovium involved by rheumatoid arthritis. A study with monoclonal antibodies[J]. *Pathology*, 1986, 18(4): 431–437.
- [18] Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?[J]. *Nat Clin Pract Rheumatol*, 2008, 4(3): 128–135.
- [19] Cross A, Barnes T, Bucknall RC, et al. Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints[J]. *J Leukoc Biol*, 2006, 80(3): 521–528.
- [20] Eggleton P, Wang L, Penhallow J, et al. Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis[J]. *Ann Rheum Dis*, 1995, 54(11): 916–923.
- [21] Tanaka D, Kagari T, Doi H, et al. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis[J]. *Immunology*, 2006, 119(2): 195–202.
- [22] Fossati G, Moots RJ, Bucknall RC, et al. Differential role of neutrophil Fcγ receptor IIIB (CD16) in phagocytosis, bacterial killing, and responses to immune complexes[J]. *Arthritis Rheum*, 2002, 46(5): 1351–1361.
- [23] Lefrançais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G[J]. *Proc Natl Acad Sci USA*, 2012, 109(5): 1673–1678.
- [24] Elsaid KA, Jay GD, Chichester CO. Detection of collagen type II and proteoglycans in the synovial fluids of patients diagnosed with non-infectious knee joint synovitis indicates early damage to the articular cartilage matrix[J]. *Osteoarthritis Cartilage*, 2003, 11(9): 673–680.
- [25] Baici A, Salgam P, Cohen G, et al. Action of collagenase and elastase from human polymorphonuclear leukocytes on human

- articular cartilage[J]. Rheumatol Int, 1982, 2(1): 11-16.
- [26] Adkison AM, Raptis SZ, Kelley DG, et al. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis[J]. J Clin Invest, 2002, 109(3): 363–371.
- [27] Fernandes RMSN, da Silva NP, Sato EI. Increased myeloperoxidase plasma levels in rheumatoid arthritis[J]. *Rheumatol Int*, 2012, 32(6): 1605–1609.
- [28] Odobasic D, Yang Y, Muljadi RCM, et al. Endogenous myeloperoxidase is a mediator of joint inflammation and damage in experimental arthritis[J]. *Arthritis Rheumatol*, 2014, 66(4): 907–917.
- [29] Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase[J]. *Science*, 2002, 296(5577): 2391–2394.
- [30] Klinke A, Nussbaum C, Kubala L, et al. Myeloperoxidase attracts neutrophils by physical forces[J]. *Blood*, 2011, 117(4): 1350–1358.
- [31] Raza K, Scheel-Toellner D, Lee CY, et al. Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis[J]. Arthritis Res Ther, 2006, 8(4): R120.
- [32] Weinmann P, Moura RA, Caetano-Lopes JR, et al. Delayed neutrophil apoptosis in very early rheumatoid arthritis patients is abrogated by methotrexate therapy[J]. *Clin Exp Rheumatol*, 2007, 25(6): 885–887.
- [33] Lupia E, Montrucchio G, Battaglia E, et al. Role of tumor necrosis factor-α and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis[J]. Eur J Immunol, 1996, 26(8): 1690–1694.
- [34] Wright HL, Chikura B, Bucknall RC, et al. Changes in expression of membrane TNF, NF-κB activation and neutrophil apoptosis during active and resolved inflammation[J]. *Ann Rheum Dis*, 2011, 70(3): 537–543.
- [35] Assi LK, Wong SH, Ludwig A, et al. Tumor necrosis factor αactivates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint[J]. *Arthritis Rheum*, 2007, 56(6): 1776–1786.
- [36] Tanaka S. Emerging anti-osteoclast therapy for rheumatoid arthritis[J]. *J Orthop Sci*, 2018, 23(5): 717–721.
- [37] Wei F, Chang Y, Wei W. The role of BAFF in the progression of rheumatoid arthritis[J]. *Cytokine*, 2015, 76(2): 537–544.
- [38] Chakravarti A, Raquil MA, Tessier P, et al. Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption[J]. *Blood*, 2009, 114(8): 1633–1644.
- [39] Talbot J, Bianchini FJ, Nascimento DC, et al. CCR2 expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis[J]. *Arthritis Rheumatol*, 2015, 67(7): 1751–1759.
- [40] Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression[J]. Front Immunol, 2014, 5: 508.
- [41] Tecchio C, Cassatella MA. Neutrophil-derived cytokines involved in physiological and pathological angiogenesis[J].

- Chem Immunol Allergy, 2014, 99: 123-137.
- [42] Vono M, Lin A, Norrby-Teglund A, et al. Neutrophils acquire the capacity for antigen presentation to memory CD4<sup>+</sup> T cells *in vitro* and *ex vivo*[J]. *Blood*, 2017, 129(14): 1991–2001.
- [43] Cross A, Bucknall RC, Cassatella MA, et al. Synovial fluid neutrophils transcribe and express class II major histocompatibility complex molecules in rheumatoid arthritis[J]. *Arthritis Rheum*, 2003, 48(10): 2796–2806.
- [44] Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis[J]. Sci Transl Med, 2013, 5(178): 178ra40.
- [45] Papadaki G, Kambas K, Choulaki C, et al. Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation[J]. Eur J Immunol, 2016, 46(11): 2542–2554.
- [46] Aleyd E, Al M, Tuk CW, et al. IgA complexes in plasma and synovial fluid of patients with rheumatoid arthritis induce neutrophil extracellular traps via FcαRI[J]. *J Immunol*, 2016, 197(12): 4552–4559.
- [47] Demoruelle MK, Harrall KK, Ho L, et al. Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients[J]. *Arthritis Rheumatol*, 2017, 69(6): 1165–1175.
- [48] Pérez-Sánchez C, Ruiz-Limón P, Aguirre MA, et al. Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients[J]. J Autoimmun, 2017, 82: 31–40.
- [49] Chang HH, Dwivedi N, Nicholas AP, et al. The W620 polymorphism in PTPN22 disrupts its interaction with peptidylarginine deiminase type 4 and enhances citrullination and NETosis[J]. Arthritis Rheumatol, 2015, 67(9): 2323–2334.
- [50] Dwivedi N, Upadhyay J, Neeli I, et al. Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps[J]. Arthritis Rheum, 2012, 64(4): 982–992.
- [51] Pratesi F, Dioni I, Tommasi C, et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps[J]. *Ann Rheum Dis*, 2014, 73(7): 1414–1422.
- [52] Sur Chowdhury C, Giaglis S, Walker UA, et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility[J]. Arthritis Res Ther, 2014, 16(3): R122.
- [53] Spengler J, Lugonja B, Jimmy Ytterberg A, et al. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid[J]. *Arthritis Rheumatol*, 2015, 67(12): 3135–3145.
- [54] Yu Y, Koehn CD, Yue Y, et al. Celastrol inhibits inflammatory stimuli-induced neutrophil extracellular trap formation[J]. *Curr Mol Med*, 2015, 15(4): 401–410.
- [55] Carmona-Rivera C, Carlucci PM, Moore E, et al. Synovial fibroblast-neutrophil interactions promote pathogenic adaptive

- immunity in rheumatoid arthritis[J]. *Sci Immunol*, 2017, 2(10): eaag3358.
- [56] Sohn DH, Rhodes C, Onuma K, et al. Local Joint inflammation and histone citrullination in a murine model of the transition from preclinical autoimmunity to inflammatory arthritis[J]. *Arthritis Rheumatol*, 2015, 67(11): 2877–2887.
- [57] Carmona-Rivera C, Bicker KL, Thompson PR, et al. Response to comment on "Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis"[J]. Sci Immunol, 2018, 3(21): eaar3701.
- [58] Johansson L, Pratesi F, Brink M, et al. Antibodies directed against endogenous and exogenous citrullinated antigens predate the onset of rheumatoid arthritis[J]. Arthritis Res Ther, 2016, 18(1): 127.
- [59] Corsiero E, Bombardieri M, Carlotti E, et al. Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs[J]. Ann Rheum Dis, 2016, 75(10): 1866–1875.
- [60] Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis[J]. *PLoS One*, 2012, 7(5): e35296.
- [61] Darrah E, Andrade F. Rheumatoid arthritis and citrullination[J]. *Curr Opin Rheumatol*, 2018, 30(1): 72–78.
- [62] Konig MF, Abusleme L, Reinholdt J, et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis[J]. Sci Transl Med, 2016, 8(369): 369ra176.
- [63] Shi J, Andrade F. Comment on "Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis" [J]. *Sci Immunol*, 2018, 3(21): eaao6234.
- [64] Romero V, Fert-Bober J, Nigrovic PA, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis[J]. Sci Transl Med, 2013, 5(209): 209ra150.
- [65] Darrah E, Rosen A, Giles JT, et al. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis[J]. Ann Rheum Dis, 2012, 71(1): 92–98.
- [66] van de Sande MGH, de Hair MJH, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase[J]. *Ann Rheum Dis*, 2011, 70(5): 772–777.
- [67] Nielen MMJ, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors[J]. Arthritis Rheum, 2004, 50(2): 380–386.
- [68] Deane KD, Striebich CC, Goldstein BL, et al. Identification of undiagnosed inflammatory arthritis in a community health fair screen[J]. Arthritis Rheum, 2009, 61(12): 1642–1649.
- [69] Catrina AI, Jimmy YA, Reynisdottir G, et al. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis[J]. *Nat Rev Rheumatol*, 2014, 10(11): 645–653.
- [70] Holers VM, Demoruelle MK, Kuhn KA, et al. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to

- destruction[J]. Nat Rev Rheumatol, 2018, 14(9): 542-557.
- [71] Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?[J]. *Arthritis Rheum*, 2012, 64(6): 1756–1761.
- [72] Willis VC, Demoruelle MK, Derber LA, et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease[J]. Arthritis Rheum, 2013, 65(10): 2545–2554.
- [73] Demoruelle MK, Bowers E, Lahey LJ, et al. Antibody responses to citrullinated and noncitrullinated antigens in the sputum of subjects with rheumatoid arthritis and subjects at risk for development of rheumatoid arthritis[J]. *Arthritis Rheumatol*, 2018, 70(4): 516–527.
- [74] Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis[J]. *J Clin Invest*, 2006, 116(12): 3183–3194.
- [75] Lugli EB, Correia R, Fischer R, et al. Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis[J]. *Arthritis Res Ther*, 2015, 17: 9.
- [76] Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells[J]. Ann Rheum Dis, 2008, 67(10): 1488–1492.
- [77] Eriksson K, Nise L, Kats A, et al. Prevalence of periodontitis in patients with established rheumatoid arthritis: a Swedish population based case-control study[J]. *PLoS One*, 2016, 11(5): e0155956.
- [78] Mikuls TR, Payne JB, Yu F, et al. Periodontitis and *Porphyromonas gingivalis* in patients with rheumatoid arthritis[J]. *Arthritis Rheumatol*, 2014, 66(5): 1090–1100.

- [79] Reichert S, Schlumberger W, Dähnrich C, et al. Association of levels of antibodies against citrullinated cyclic peptides and citrullinated α-enolase in chronic and aggressive periodontitis as a risk factor of Rheumatoid arthritis: a case control study[J]. J Transl Med, 2015, 13: 283.
- [80] Seror R, Le Gall-David S, Bonnaure-Mallet M, et al. Association of anti-Porphyromonas gingivalis antibody titers with nonsmoking status in early rheumatoid arthritis: results from the prospective French cohort of patients with early rheumatoid arthritis[J]. Arthritis Rheumatol, 2015, 67(7): 1729–1737.
- [81] Potempa J, Mydel P, Koziel J. The case for periodontitis in the pathogenesis of rheumatoid arthritis[J]. *Nat Rev Rheumatol*, 2017, 13(10): 606–620.
- [82] Vitkov L, Hannig M, Minnich B, et al. Periodontal sources of citrullinated antigens and TLR agonists related to RA[J]. Autoimmunity, 2018, 51(6): 304–309.
- [83] Goulas T, Mizgalska D, Garcia-Ferrer I, et al. Structure and mechanism of a bacterial host-protein citrullinating virulence factor, *Porphyromonas gingivalis* peptidylarginine deiminase[J]. *Sci Rep*, 2015, 5: 11969.
- [84] Bereta G, Goulas T, Madej M, et al. Structure, function, and inhibition of a genomic/clinical variant of *Porphyromonas* gingivalis peptidylarginine deiminase[J]. *Protein Sci*, 2019, 28(3): 478–486.
- [85] Montgomery AB, Kopec J, Shrestha L, et al. Crystal structure of *Porphyromonas gingivalis* peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis[J]. *Ann Rheum Dis*, 2016, 75(6): 1255–1261.
- [86] Chapman EA, Lyon M, Simpson D, et al. Caught in a trap? Proteomic analysis of neutrophil extracellular traps in rheumatoid arthritis and systemic lupus erythematosus[J]. *Front Immunol*, 2019, 10: 423.

RECEIVE IMMEDIATE NOTIFICATION FOR EARLY RELEASE ARTICLES PUBLISHED ONLINE

To be notified by e-mail when *Journal* early release articles are published online, sign up at **jbr-pub.org.cn**.